Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : NX210c is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : NX210c
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Centre for Human Drug Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NX210c is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : NX210c
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Centre for Human Drug Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
